SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity
특정 체액 면역이 없는 1차 항체 결핍 환자의 중증 및 치명적인 COVID-19에서 SARS-CoV-2 T 세포 반응
Article
[키워드] activated
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
administration
Analysis
analyzed
antibody
autoantibodies
autoantibody
Blood
CD169
CD4
cellular
characterized
clearance
clinical disease
Comorbidities
Comorbidity
convalescent
convalescent plasma
Convalescent plasma (CP)
coronavirus
coronavirus disease
Coronavirus disease 2019
Coronavirus disease 2019 (COVID-19)
COVID-19
cytokine
deficiency
detectable
elevated
examined
excluded
expression
fatal COVID-19
flow cytometry
healthy individuals
heterogeneous
humoral
humoral immune response
IgG
Immunity
immunodeficiency
immunological
immunological mechanism
Inborn errors
indicate
innate immune response
Innate immunity
interferon
interferons
lack
marker
median
monoclonal antibody
Monocytes
morbidity
Mortality
mucosal
naïve
nucleocapsid
outcome
Patient
patients
peptide
peptide pool
Peripheral blood
persistence
phenotype
primary antibody
primary antibody deficiency (PAD)
Primary immunodeficiencies
primary immunodeficiencies (PID)
producing
Prophylactic
respiratory
response
Risk factors
robust
SARS-CoV-2
SARS-CoV-2 immunity
SARS-CoV-2 RNA
SARS-CoV-2 spike
SARS-CoV-2 viral shedding
seronegative
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Severe case
severe cases
severe COVID-19 patient
SIGLEC1
Specific
T cell
T cell response
T cells
Treatment
type I interferon
type I interferon response
type I interferons
undetectable
Viral
viral clearance
viral shedding
with COVID-19
[DOI] 10.3389/fimmu.2022.840126 PMC 바로가기 [Article Type] Article
[DOI] 10.3389/fimmu.2022.840126 PMC 바로가기 [Article Type] Article